Side-by-side comparison of AI visibility scores, market position, and capabilities
Minneapolis life science tools (NASDAQ: TECH) at $1.19B FY2024 revenue; Q2 FY2025 9% organic growth, R&D Systems cytokines/antibodies + RNAscope spatial biology (500K+ products) competing with Thermo Fisher for biopharma reagents.
Bio-Techne Corporation is a Minneapolis, Minnesota-based life sciences tools company — publicly traded on NASDAQ (NASDAQ: TECH) as an S&P 500 Health Care component — developing, manufacturing, and selling biological reagents, proteins, antibodies, assay kits, analytical instruments, and spatial biology tools for pharmaceutical drug discovery, bioprocessing, academic research, and clinical diagnostics through approximately 3,000 employees across 34 global locations with an annual revenue of $1.19 billion in fiscal year 2024. In Q2 fiscal 2025, Bio-Techne reported organic revenue growth of 9% to $297 million, demonstrating recovery from the funding-constrained biotech environment of 2023-2024. The company operates through two segments: Protein Sciences (approximately 75% of revenue, including the R&D Systems portfolio of 500,000+ life science products — cytokines, growth factors, antibodies, ELISAs, and recombinant proteins — as well as ProteinSimple analytical instruments and Tocris Bioscience chemical biology tools) and Diagnostics and Genomics (approximately 25%, including Advanced Cell Diagnostics' RNAscope technology for gene expression visualization in intact tissue and Lunaphore's COMET spatial biology automation platform acquired in 2023). Bio-Techne launched approximately 800 new products in fiscal 2024 and maintains a catalog of 6,000+ recombinant proteins spanning 35 species. The company has a market capitalization of approximately $9.59 billion.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.